Angiomics is a start-up biopharmaceutical company with the mission of discovering drugs from medicinal plants. The focus will be on accelerating wound healing. At present, the $5 billion global wound care market consists mainly of products that, at best, only create environments conducive to healing. The future of the wound care market lies in the promise of products that go beyond facilitative wound repair and actively accelerate the healing process. Angiomics already possesses a patent-protected technology that accelerates a key step in wound healing. Founded by three PhD students at the Unversity of Coventry, Angiomics is determined to stay in the lead by employing cutting-edge technologies in the drug discivery process.

Anuj Madhok
Sasidhar Chodagam
Shiladitya Sengupta